Clinical Trials
7 trialsNCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02900560 2022-06-10
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Translational Research in Oncology
Phase 2 Terminated
NCT02811497 2021-04-01
METADUR
University Health Network, Toronto
Phase 2 Completed
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT01478685 2019-11-12
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
Phase 1 Completed
NCT00842582 2016-11-02
Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer
Loyola University
Phase 1 Withdrawn
NCT00529022 2013-02-20
Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1 Completed